NRAS (1-186) Mouse Monoclonal Antibody [Clone ID: AT2G9]

SKU AM09391PU-N

NRAS (1-186) mouse monoclonal antibody, clone AT2G9, Purified

Product Data

• Clone Name: AT2G9
• Application: ELISA, FC, IF, WB
• Recommended Dilution: ELISA.; Western blot (1:500 - 1:5000; recommended starting dilution is 1:1000).; Immunocytochemistry / Immunoflourescence.; Flow cytometry.
• Reactivity: Human
• Antibody Host: Mouse
• Isotype: IgG2a
• Clonality: Monoclonal
• Immunogen: Recombinant human NRAS (1-186aa) purified from E. coli
• Specificity: The antibody recognizes human RAS at aa 1-186. Other species not tested.
• Buffer: PBS, pH 7.4 containing 0.02% Sodium Azide and 10% Glycerol; State: Purified; State: Liquid purified Ig fraction
• Concentration: lot specific
• Purification: Protein-G affinity chromatography
• Conjugation: Unconjugated
• Storage: Store undiluted at 2-8°C for up to two weeks or (in aliquots) at -20°C for longer.; Avoid repeated freezing and thawing.
• Stability: Shelf life: one year from despatch.
• Shipping: Blue Ice
• Gene Name: neuroblastoma RAS viral oncogene homolog
• Database Link:
  P01111
• Background: The Ras protein is a subfamily of small GTPases that are involved in signal transduction. They are activated by ligand-binding receptor tyrosine kinases such as EGFR, PDGFR, CSF and FGF. These kinases transiently convert RAS-GDP (inactive form) to RAS-GTP, the active form of RAS. The main genes are HRAS, NRAS and KRAS.
• Synonyms: NRAS, HRAS1, KRAS, KRAS2, RASK2, HRAS, HRAS1

Reference Data

• Protein Families: Druggable Genome
• Protein Pathways: Acute myeloid leukemia, Axon guidance, B cell receptor signaling pathway, Bladder cancer, Chemokine signaling pathway, Chronic myeloid leukemia, Endometrial cancer, ErbB signaling pathway, Fc epsilon RI signaling pathway, Gap junction, Glioma, GnRH signaling pathway, Insulin signaling pathway, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Non-small cell lung cancer, Pathways in cancer, Prostate cancer, Regulation of actin cytoskeleton, Renal cell carcinoma, T cell receptor signaling pathway, Thyroid cancer, Tight junction, VEGF signaling pathway